What Is Veradermics, Incorporated (MANE) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Veradermics, Incorporated's intrinsic value is estimated at $52.29, suggesting the stock is overvalued at its current price of $123.70. With 9 out of 10 models flagging downside (-57.7% average return), the market may be pricing in unsustainable growth. Notably, First Chicago sees the most upside at +30.2% (fair value: $161.07), while Dynamic NAV is the most conservative at -94.3% ($7.03). The spread between these extremes — +124.5% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About MANE?
10 of 13 models are currently active for MANE. Of these, 1 model suggests upside while 9 models suggest overvaluation. The Bayesian DCF estimates MANE's intrinsic value at $29.90, implying -75.8% downside from the current price. See which stocks rank higher →
How Does MANE Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, MANE ranks #195 by Quality of Company score. CirclFi's QOC score of 5.1/10 evaluates 32 fundamental signals. A score of 5.1 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Veradermics, Incorporated operates in a sector where revenue per drug is a critical driver of valuation. Investors evaluating MANE should weigh these sector-specific dynamics alongside our model-derived fair values.
Is MANE a Value Trap?
The Value Trap algorithm is not active for MANE. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Veradermics, Incorporated. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Veradermics, Incorporated's fundamental quality profile registers 5.1/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +124.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every MANE valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across MANE's 10 active models, average confidence is 30%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad